KESTRA MEDICAL TECHNOLOGIES (KMTS) Fundamental Analysis & Valuation

NASDAQ:KMTS • BMG524411052

Current stock price

22.81 USD
+2.4 (+11.76%)
At close:
22.696 USD
-0.11 (-0.5%)
After Hours:

This KMTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KMTS Profitability Analysis

1.1 Basic Checks

  • In the past year KMTS has reported negative net income.
  • In the past year KMTS has reported a negative cash flow from operations.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • KMTS's Return On Assets of -39.05% is on the low side compared to the rest of the industry. KMTS is outperformed by 62.77% of its industry peers.
  • KMTS has a Return On Equity (-51.43%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.05%
ROE -51.43%
ROIC N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • KMTS's Gross Margin of 48.75% is in line compared to the rest of the industry. KMTS outperforms 44.68% of its industry peers.
  • KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. KMTS Health Analysis

2.1 Basic Checks

  • KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, KMTS has about the same amount of shares outstanding.
  • The debt/assets ratio for KMTS has been reduced compared to a year ago.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 2025 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 5.39 indicates that KMTS is not in any danger for bankruptcy at the moment.
  • KMTS has a better Altman-Z score (5.39) than 79.26% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that KMTS is not too dependend on debt financing.
  • KMTS has a better Debt to Equity ratio (0.15) than 60.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 5.39
ROIC/WACCN/A
WACC8.91%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • KMTS has a Current Ratio of 7.32. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of KMTS (7.32) is better than 86.70% of its industry peers.
  • KMTS has a Quick Ratio of 7.32. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
  • KMTS has a Quick ratio of 7.32. This is amongst the best in the industry. KMTS outperforms 89.36% of its industry peers.
Industry RankSector Rank
Current Ratio 7.32
Quick Ratio 7.32
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. KMTS Growth Analysis

3.1 Past

  • KMTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.57%.
  • Looking at the last year, KMTS shows a very strong growth in Revenue. The Revenue has grown by 59.06%.
EPS 1Y (TTM)-49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.04%
Revenue 1Y (TTM)59.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%62.7%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.77% on average over the next years.
  • Based on estimates for the next years, KMTS will show a very strong growth in Revenue. The Revenue will grow by 46.36% on average per year.
EPS Next Y-18.29%
EPS Next 2Y-5.33%
EPS Next 3Y3.77%
EPS Next 5YN/A
Revenue Next Year59.64%
Revenue Next 2Y51.06%
Revenue Next 3Y48.61%
Revenue Next 5Y46.36%

3.3 Evolution

KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M 250M
KMTS Yearly EPS VS EstimatesKMTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. KMTS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KMTS. In the last year negative earnings were reported.
  • Also next year KMTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.33%
EPS Next 3Y3.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KMTS Dividend Analysis

5.1 Amount

  • KMTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KMTS Fundamentals: All Metrics, Ratios and Statistics

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (4/17/2026, 8:25:31 PM)

After market: 22.696 -0.11 (-0.5%)

22.81

+2.4 (+11.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17
Earnings (Next)07-16
Inst Owners50.49%
Inst Owner ChangeN/A
Ins Owners0.9%
Ins Owner Change-4.78%
Market Cap1.33B
Revenue(TTM)83.72M
Net Income(TTM)-148.12M
Analysts86.15
Price Target28.56 (25.21%)
Short Float %12.75%
Short Ratio9.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.11%
Min EPS beat(2)-5.83%
Max EPS beat(2)-0.39%
EPS beat(4)1
Avg EPS beat(4)-69.21%
Min EPS beat(4)-312.7%
Max EPS beat(4)42.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)5.28%
Max Revenue beat(2)6.85%
Revenue beat(4)4
Avg Revenue beat(4)6.41%
Min Revenue beat(4)5.28%
Max Revenue beat(4)7.26%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.99%
PT rev (3m)-1.47%
EPS NQ rev (1m)-4.77%
EPS NQ rev (3m)-5.04%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-1.59%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)1.43%
Revenue NY rev (1m)2.24%
Revenue NY rev (3m)2.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.9
P/FCF N/A
P/OCF N/A
P/B 4.62
P/tB 4.62
EV/EBITDA N/A
EPS(TTM)-3.91
EYN/A
EPS(NY)-2.25
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS1.43
BVpS4.93
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -39.05%
ROE -51.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.75%
FCFM N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 396.8%
Cap/Sales 38.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.32
Quick Ratio 7.32
Altman-Z 5.39
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)226.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)88.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.04%
EPS Next Y-18.29%
EPS Next 2Y-5.33%
EPS Next 3Y3.77%
EPS Next 5YN/A
Revenue 1Y (TTM)59.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%62.7%
Revenue Next Year59.64%
Revenue Next 2Y51.06%
Revenue Next 3Y48.61%
Revenue Next 5Y46.36%
EBIT growth 1Y-82.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.45%
EBIT Next 3Y12.33%
EBIT Next 5YN/A
FCF growth 1Y-19.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.44%
OCF growth 3YN/A
OCF growth 5YN/A

KESTRA MEDICAL TECHNOLOGIES / KMTS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KMTS.


What is the valuation status of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a valuation rating of 0 / 10 to KESTRA MEDICAL TECHNOLOGIES (KMTS). This can be considered as Overvalued.


How profitable is KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

KESTRA MEDICAL TECHNOLOGIES (KMTS) has a profitability rating of 1 / 10.


Can you provide the financial health for KMTS stock?

The financial health rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) is 6 / 10.